MedTrace Logo

Improving Retreatment Success (IMPRESS)

NCT02114684 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 197

Last updated 2019-08-05

Study results available
· View outcomes & findings →

Summary

This is an open label randomized controlled clinical trial comparing two regimens for treatment of smear-positive pulmonary TB, among patients previously treated for TB. The primary objective is to determine if a moxifloxacin-containing regimen, substituting moxifloxacin for ethambutol, of 24 weeks duration is superior to a control regimen of 24 weeks duration in improving treatment outcomes in patients with recurrent TB and shortens the duration of TB treatment.

Conditions

  • Recurrent Tuberculosis

Interventions

DRUG

moxifloxacin

\[isoniazid (H), rifampicin (R), pyrazinamide (Z), moxifloxacin (M)\]

Sponsors & Collaborators

  • Centre for the AIDS Programme of Research in South Africa

    lead NETWORK

Principal Investigators

  • Nesri Padayatchi, MBChB, MSc · Centre for the AIDS Programme of Research in South Africa

  • Kogieleum Naidoo, MBChB · Centre for the AIDS Programme of Research in South Africa

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2017-07-31
Completion
2017-07-17

Countries

  • South Africa

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02114684 on ClinicalTrials.gov